A phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CART cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory CD19 expressing hematologic malignancies (NCT05665062) Meeting Abstract
| Authors: | Palomba, M. L.; Caimi, P. F.; Mei, M.; Hernandez-Ilizaliturri, F.; Shouse, G.; Winter, A. M.; Yedinak, G.; Mou, D.; Huang, N.; Moua, A.; Oft, M.; Aspuria, P. J.; Mehta-Damani, A.; Rizvi, N.; Unabia, S.; Taylor, P.; McLeroy, J.; Cortese, M. J. |
| Abstract Title: | A phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CART cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory CD19 expressing hematologic malignancies (NCT05665062) |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 3453 |
| Language: | English |
| ACCESSION: | WOS:001412753100018 |
| DOI: | 10.1182/blood-2024-202090 |
| PROVIDER: | wos |
| Notes: | Source: Wos |
